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Summary
Clostridium difﬁcile infection (CDI) is a challenging
threat to human health. Infections occur after disrup-
tion of the normal microbiota, most commonly
through the use of antibiotics. Current treatment for
CDI largely relies on the broad-spectrum antibiotics
vancomycin and metronidazole that further disrupt
the microbiota resulting in frequent recurrence, high-
lighting the need for C. difﬁcile-speciﬁc antimicro-
bials. The cell surface of C. difﬁcile represents a
promising target for the development of new drugs.
C. difﬁcile possesses a highly deacetylated peptido-
glycan cell wall containing unique secondary cell
wall polymers. Bound to the cell wall is an essential
S-layer, formed of SlpA and decorated with an addi-
tional 28 related proteins. In addition to the S-layer,
many other cell surface proteins have been identi-
ﬁed, including several with roles in host coloniza-
tion. This review aims to summarize our current
understanding of these different C. difﬁcile cell
surface components and their viability as therapeutic
targets.
Introduction
Clostridium difﬁcile is a Gram positive, spore-forming,
anaerobic bacterium and is the leading cause of antibi-
otic-associated nosocomial diarrhoea (Rupnik et al.,
2009). Although the use of antibiotics has undoubtedly
had an enormous positive impact on human health over
the past seven decades, it is unfortunate that their use is
also the main risk factor for C. difﬁcile infection (CDI).
Hospitalized patients are frequently treated with broad-
spectrum antibiotics, both as prophylactics and to treat
infection, resulting in catastrophic damage to the gut
microbiota (Dethlefsen et al., 2008). C. difﬁcile can
exploit the resulting dysbiosis to colonize and proliferate
in the gut (Lawley et al., 2009).
C. difﬁcile pathogenesis is a three-step process that
begins with disruption of the gut microbiota (Smits et al.,
2016). This is followed by germination of indigenous or
ingested spores, which starts the colonization phase –
involving the attachment of the bacterium to the host
intestinal epithelium and multiplication both at the sur-
face and in the lumen. Colonization is required for the
ﬁnal phase of virulence, the release of toxins and the
onset of disease symptoms. Most C. difﬁcile clinical iso-
lates produce two related toxins, TcdA and TcdB, that
belong to the large clostridial cytotoxin family (Jank and
Aktories, 2008). Both of these toxins act by glucosylating
small GTPases including Rho, Rac and Cdc42. The
action of these toxins is responsible for the clinical mani-
festations of disease, ranging from mild diarrhoea
through to life-threatening inﬂammatory complications
such as pseudomembranous colitis and toxic megacolon
(Smits et al., 2016). Thirty-day mortality can exceed 30%
in elderly populations (McGowan et al., 2011). Since
2001, the emergence of highly transmissible epidemic
strains and advances in the availability of genetic tools
has increased interest and rapidly advanced our under-
standing of this important pathogen (McDonald et al.,
2005; Ng et al., 2013; Dembek et al., 2015). Despite
these improvements, our understanding of C. difﬁcile vir-
ulence is still in its infancy. It is clear that bacterial cell
surface components will be crucial in the interaction
between the bacterium and the host. However, the
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molecular details of these interactions are still largely
uncharacterized.
Recent studies focussing on the C. difﬁcile envelope
have identiﬁed and characterized several cell wall poly-
mers, as well as numerous surface proteins (Table 1).
Many of these macromolecules are unique to C. difﬁcile
making the cell envelope a prime target for the develop-
ment of species-speciﬁc therapeutics. This review will
describe our current understanding of C. difﬁcile cell
envelope architecture, highlighting the potential for novel
drugs and vaccines to treat and prevent CDI.
C. difﬁcile cell wall
Peptidoglycan
Peptidoglycan (PG) is an essential component of the
cell wall with pleiotropic functions, including mainte-
nance of cell shape and integrity, and anchoring cell
wall proteins (CWP). PG structure is largely conserved,
consisting of long glycan polymers cross-linked by
short peptide chains. The polysaccharide backbone
is composed of polymers of the b-1?4 linked
disaccharide N-acetylglucosamine-N-acetylmuramic acid
(GlcNAc-MurNAc). A short peptide stem, which varies
between bacterial species, is linked to the D-lactoyl
group of MurNAc [reviewed in (Vollmer et al., 2008)].
Muropeptide analysis of digested C. difﬁcile PG identi-
ﬁed the tetrapeptide stem: L-Ala-D-Glu-A2pm-D-Ala
(A2pm: 2,6-diaminopimelic acid) (Fig. 1) (Peltier et al.,
2011). Cross-linking of the glycan strands in bacteria
most commonly occurs via 4-3 cross-links catalysed by
D,D-transpeptidases, the essential target of b-lactam
antibiotics (reviewed in Vollmer et al., 2008). However,
C. difﬁcile displays a very high abundance of 3-3 pep-
tide cross-links generated by at least two L,D-transpepti-
dases. The abundance of 3-3 cross-links in C. difﬁcile
PG is increased by the partial inhibition of D,D-transpep-
tidases by ampicillin, suggesting that the L,D-transpepti-
dases are insensitive to ampicillin. Despite this,
C. difﬁcile remains susceptible to ampicillin, suggesting
that 4-3 cross-linking is essential for PG assembly
(Peltier et al., 2011).
Fig. 1. Structure of the conserved cell wall polymers of Clostridium difﬁcile. PG: C. difﬁcile produces a peptidoglycan characterized by a very
high degree of N-acetylglucosamine deacetylation (up to 93%), the stem peptide L-Ala-D-Glu-A2pm-D-Ala-D-Ala and an unusually high degree
(73%) of 3-3 cross-links. PS-II: a conserved cell wall polysaccharide polymer with a core hexasaccharide repeating unit of [?6)-b-D-Glcp-
(1?3)-b-D-GalpNAc-(1?4)-a-D-Glcp-(1?4)-[b-D-Glcp- (1?3]-b-D-GalpNAc-(1?3)-a-D-Manp-(1?P?]. PS-III/LTA: a conserved lipid-anchored cell
wall polysaccharide in the extended lipoteichoic acid family with a core repeating unit of [?6)-a-D-GlcpNAc-(1?3)-[?P-6]-a-D-GlcpNAc-(1?2)-
D-GroA]. This repeat unit is linked to ?6)-b-D-Glcp-(1?6)-b-D-Glcp-(1?6)-b-D-Glcp-(1?1)-Gro, with the terminal glycerol esteriﬁed with C14,
C16, or C18 saturated or mono-unsaturated fatty acids.
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N-deacetylation or O-acetylation of either GlcNAc or
MurNAc introduces further variation in PG structure
between bacterial species. C. difﬁcile displays very high
levels of GlcNAc N-deacetylation (89–93%), while all
MurNAc residues remain fully acetylated. The proportion
of N-deacetylation observed is higher than that reported
for other Gram positive bacteria (Peltier et al., 2011). In
addition to this naturally high level of PG deacetylation,
the percentage of acetylated GlcNAc residues decreases
more than twofold in response to the introduction of lyso-
zyme (Ho et al., 2014). Lysozyme is a key effector of
the innate immune system that cleaves the PG back-
bone (Bevins and Salzman, 2011); however, PG
deacetylation can confer resistance (Vollmer and
Tomasz, 2000). Lysozyme induces expression of csfV,
encoding an extracytoplasmic r factor, which in turn
upregulates expression of the polysaccharide deacety-
lase PdvA, resulting in further PG deacetylation. csfV
mutants are severely attenuated in the hamster model of
infection (Ho et al., 2014).
A notable observation is the presence of a functional
vanGcd cluster in 85% of available C. difﬁcile genomes.
Vancomycin, an antibiotic of last resort used to treat sev-
ere or recurrent C. difﬁcile infections, inhibits cell wall
synthesis through interaction with the terminal D-Ala-D-
Ala of PG precursors (Reynolds, 1989; Johnson et al.,
2014). Resistance to vancomycin can be conferred via
modiﬁcation of the terminal D-Ala-D-Ala. For example,
Enterococcus faecalis achieves low-level resistance
through synthesis of D-Ala-D-Ser precursors by enzymes
encoded in the vanG operon (Depardieu et al., 2003).
Genes homologous to those in the vanG operon have
been identiﬁed in the majority of C. difﬁcile strains tested
(Ammam et al., 2012; Peltier et al., 2013) and are able
to synthesize D-Ala-D-ser precursors in response to sub-
lethal concentrations of vancomycin (Ammam et al.,
2013) although this is debated (Peltier et al., 2013).
Introduction of the vanGcd operon into a vancomycin-
sensitive strain of E. coli conferred low-level resistance
to vancomycin and a C. difﬁcile mutant lacking this clus-
ter displays a slightly lower vancomycin MIC relative to
wild-type (Ammam et al., 2013). The C. difﬁcile genome
also contains genes homologous to vanW and vanZ,
although the function of these genes remains unknown
(Ammam et al., 2012). Despite this, C. difﬁcile remains
susceptible to vancomycin treatment. This observation
may be due to a number of factors including preferential
incorporation of D-Ala-D-Ala precursors by the cell wall
synthesis machinery and weak activity of the resistance
genes. However, it is possible that genomic alterations
allowing vanGcd-mediated vancomycin resistance could
emerge (Ammam et al., 2013). Another cell wall synthe-
sis inhibitor, the lipoglycodepsipeptide Ramoplanin, dis-
plays efﬁcacy against C. difﬁcile in the hamster model
and also reduces persistence of spores (Freeman et al.,
2005). This drug has shown promising results in a phase
II trial (Pullman et al., 2004) and was fast tracked for
development by the US Food and Drug Administration.
Ramoplanin was acquired by Nanotherapeutics in 2009
and is due to begin a new phase IIb clinical trial in 2016.
An alternative approach to disrupting PG is the use of
phage endolysins that degrade the cell wall resulting in
cell lysis and death. The ΦCD27 endolysin, CD27L1-
179, can effectively lyse C. difﬁcile cells (Mayer et al.,
2011) by cleaving the bond between MurNAc and the
ﬁrst L-Ala (Peltier et al., 2015). As PG architecture is
more highly conserved than proteinaceous phage recep-
tors, the endolysin is effective against diverse strains of
C. difﬁcile. However, the wider effect of such endolysins
on the gut microbiota remains to be tested.
Secondary cell wall polysaccharides
To date, three anionic polymers have been identiﬁed on
the cell surface of C. difﬁcile. The ﬁrst described
polysaccharide (PS-I) consists of a branched penta-gly-
cosylphosphate repeating unit, originally identiﬁed in a
ribotype 027 strain (Ganeshapillai et al., 2008). PS-I is
only found in a minority of strains. The two other
polysaccharides, a polymer of hexaglycosylphosphate
repeat units (PS-II) and a lipid bound glycosylphosphate
polymer (PS-III), are more widely distributed and have
been found in all strains examined to date (Fig. 1)
(Ganeshapillai et al., 2008; Reid et al., 2012). PS-I and
PS-II have been described as teichoic acid-like, although
they differ signiﬁcantly from the simple glycerol phos-
phate or ribitol phosphate classic teichoic acids (Gane-
shapillai et al., 2008; Weidenmaier and Peschel, 2008).
PS-III is a member of the extended lipoteichoic acid fam-
ily (Percy and Grundling, 2014). Although the biological
signiﬁcance of these polymers in C. difﬁcile remains
poorly understood, PS-II has been identiﬁed as the cell
wall ligand that anchors members of the CWP family to
the cell surface (see below). Additionally, evidence sug-
gests that secondary cell wall polymer synthesis may be
an essential process linked to CWP secretion (Willing
et al., 2015).
Due to the accessibility of these polymers in the cell
wall, they have been investigated as potential vaccine
targets. Glycans are T cell-independent antigens,
although when conjugated to a carrier protein, these
molecules can elicit a T-cell memory response (Berti and
Adamo, 2013). Anti-PS-I antibodies can be detected in
sera from healthy horses and chemically synthesized
PS-I has been fused to a subunit of C. difﬁcile toxin B to
form a potential dual conjugate vaccine (Jiao et al.,
2013). These preliminary studies demonstrated the
potential of cell wall polysaccharides as vaccine
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candidates. However, as PS-I is not universal between
disparate C. difﬁcile strains, PS-II and PS-III may repre-
sent more promising vaccine targets. Following exposure
to C. difﬁcile, humans naturally produce anti-PS-II anti-
bodies (Oberli et al., 2011) and elevated levels of anti-
PS-II IgM antibodies can be detected in pigs in response
to administration of non-conjugate PS-II (Bertolo et al.,
2012). Several conjugate PS-II vaccines have been
developed, using carriers including CRM197, a non-toxic
mutant of the diphtheria toxin commonly used as a car-
rier protein in commercial vaccines (Adamo et al., 2012),
and C. difﬁcile toxin fragments (Romano et al., 2014).
Both of these conjugate vaccines elicit a PS-II speciﬁc
IgG antibody response. Antibodies that react with syn-
thetic PS-III have also been detected in the blood of
C. difﬁcile-infected patients (Martin et al., 2013) and con-
jugate PS-III vaccines are able to elicit an immune
response (Cox et al., 2013). However, anti-PS-III anti-
bodies also cross-react with other members of the
Clostridium family suggesting that this lipoteichoic acid is
not C. difﬁcile-speciﬁc.
S-layer and cell wall proteins
C. difﬁcile S-layer
The bacterial surface layer (S-layer) is a proteinaceous
two-dimensional para-crystalline array coating the entire
cell (Fagan and Fairweather, 2014). S-layers are usually
composed of one or more proteins, called S-layer pro-
teins (SLPs) that self-assemble to form the array. SLPs
are among the most abundant and metabolically expen-
sive proteins in bacteria that produce them, suggesting
that they play a critical role. For example, a typical
C. difﬁcile cell has a surface area of approximately
18.85 lm2 and an S-layer unit cell of 64 nm2 containing
two protein subunits (our unpublished data). The S-layer
therefore consists of approximately 590 000 S-layer sub-
units, requiring synthesis, export and assembly of 164
subunits per second during exponential growth. C. difﬁ-
cile possesses an S-layer with square-ordered lattice
(Kawata et al., 1984), consisting of two distinct proteins,
a high-molecular weight (HMW) SLP (42–50 kDa) and a
low-molecular weight (LMW) SLP (22–38 kDa) (Cerquetti
et al., 2000). The two SLPs are generated by post-trans-
lational cleavage of a pre-protein encoded by slpA (Cal-
abi et al., 2001). The S-layer appears to be essential, as
evidenced by an inability to generate transposon-
mediated insertional mutants within the slpA gene
(Dembek et al., 2015). SlpA has three identiﬁable subdo-
mains: an N-terminal secretion signal, followed by the
highly variable LMW region and ﬁnally the HMW region
containing three tandem cell wall binding 2 motifs
(CWB2, PF04122) (Fagan et al., 2011). The signal pep-
tide directs translocation across the cell membrane via
the accessory Sec system (Fagan and Fairweather,
2011), following which the pre-protein is cleaved by the
cell wall localized cysteine protease Cwp84 (Kirby et al.,
2009; Dang et al., 2010), to generate the two SLPs. Fol-
lowing cleavage, the two SLPs form a stable heterodi-
meric complex (H/L complex; Fagan et al., 2009) that
self-assembles to form the mature S-layer. Extended
interaction domains stabilize the HMW and LMW SLP
via non-covalent interactions in the H/L complex (Fagan
et al., 2009). The CWB2 motifs in the HMW SLP anchor
the H/L complex to the cell wall via an interaction with
PS-II (Willing et al., 2015). The mechanism by which the
H/L complex assembles to form the mature S-layer is
still not understood. It is believed that S-layer self-
assembly is a thermodynamically driven process (Chung
et al., 2010) and some SLPs possess a distinct crystal-
lization domain that mediates lateral interactions in the
array (Smit et al., 2002). However, no such domain has
been identiﬁed in C. difﬁcile SlpA.
A lack of isogenic slpA mutants has greatly hampered
analysis of C. difﬁcile S-layer function. However, both
the LMW and HMW SLPs have been implicated in bind-
ing to both cultured Hep-2 cells and ex vivo human gas-
trointestinal tissue (Calabi et al., 2002). Isolated SLPs
were also observed to inhibit attachment of C. difﬁcile to
Caco-2BBE cells (Merrigan et al., 2013). In addition to a
possible adhesive role, the S-layer has also been impli-
cated in host immune activation via TLR4 (Ryan et al.,
2011). Taken together, these data suggest that the S-
layer plays a crucial role in interactions with the host but
detailed analysis of the contribution of the S-layer to
pathogenesis will require isogenic mutants. As the S-
layer is the dominant surface structure on C. difﬁcile
cells and anti-SLP antibody has been detected in sera
from convalescent patients (Wright et al., 2008). Passive
immunization with anti-SLP antibodies also showed
some promise in delaying death in the lethal hamster
model (O’Brien et al., 2005). However, active immuniza-
tion with puriﬁed SLPs alone, or SlpA in combination
with cholera toxin, did not result in signiﬁcant protection
using the same model (Ni Eidhin et al., 2008; Bruxelle
et al., 2016). SlpA is highly variable between C. difﬁcile
strains with at least 12 distinct sequence types known
(Dingle et al., 2013). An effective therapeutic or vaccine
targeting this protein would need to demonstrate protec-
tion against all types.
S-layer locus
The C. difﬁcile genome encodes 28 paralogues of SlpA
(Fagan et al., 2011) that make up the CWP family (de-
scribed below). slpA is encoded within a genomic locus
including 11 of these paralogues (Fig. 2A) and adjacent
to a cluster of polysaccharide synthesis genes thought
ª 2016 The Authors. Microbial Biotechnology published by Society for Applied Microbiology and John Wiley & Sons Ltd.
4 J. A. Kirk, O. Banerji and R. P. Fagan
to be responsible for the synthesis of PS-II (Willing et al.,
2015). Genome sequencing of a panel of 57 diverse
C. difﬁcile strains has identiﬁed a 10 kb cassette within
the S-layer locus that displays higher inter-strain variabil-
ity than the rest of the locus (Dingle et al., 2013). This
core variable S-layer cassette includes the slpA, secA2,
cwp2 and cwp66 genes, and 12 distinct cassette
sequence types have been identiﬁed to date. Interest-
ingly, one of these S-layer cassettes was found to con-
tain a 24 kb polysaccharide synthesis gene cluster
inserted in place of cwp2 (Fig. 2B). As the C. difﬁcile
S-layer is generally not thought to be glycosylated (Qazi
et al., 2009), it will be very interesting to determine if
this SlpA type is glycosylated. The sequence diversity
observed between cassette types suggests a strong
selective pressure having shaped the antigenic
types. This selective pressure can perhaps be attributed
to both the host immune response and bacteriophage
predation.
Cell wall protein family
The 28 members of the C. difﬁcile CWP family all con-
tain three tandem copies of the CWB2-anchored surface
proteins. Similar families of CWB2-containing proteins
have also been identiﬁed in C. botulinum and C. tetani
(Bruggemann et al., 2003; Sebaihia et al., 2007). Bacil-
lus anthracis also has an S-layer and related family of
CWP that share a common anchoring mechanism, the
S-layer homology (SLH) motif (Kern and Schneewind,
2008). The SLH motif is distinct to the CWB2 motif found
in C. difﬁcile surface proteins but is also found in three
tandem copies. The B. anthracis SLH motifs adopt a
pseudo-trimeric arrangement forming a three-pronged
spindle that is required for non-covalent binding to a
pyruvylated secondary cell wall polysaccharide (Mes-
nage et al., 2000; Kern et al., 2011). Given the similari-
ties to the arrangement of CWB2 motifs within SlpA and
the CWPs, it is tempting to speculate that a similar
mechanism may be responsible for anchoring these pro-
teins to the anionic polymer PS-II in the C. difﬁcile cell
wall (Willing et al., 2015). In addition to the CWB2-
anchoring domain, many of the CWPs include an addi-
tional domain that is believed to functionalize the S-layer
(Fagan and Fairweather, 2014) (Fig. 3). Only a small
number of these CWPs have been characterized in any
detail but several have been shown to play crucial roles
in the interaction between C. difﬁcile and the host.
Cwp66 is a 66 kDa protein with N-terminal CWB2
motifs. The C-terminal domain contains an apparently
surface-exposed adhesin that can mediate adherence to
Vero cells (Calabi et al., 2001; Waligora et al., 2001).
cwp66 is transcribed only in early exponential phase as
a polycistronic transcript (Savariau-Lacomme et al.,
2003).
Cwp84 has a papain class cysteine protease domain
(Savariau-Lacomme et al., 2003). Proteolytic enzymes
are frequently involved in bacterial colonization process,
serving to degrade host proteins including immunoglobu-
lin, nutrient acquisition and processing bacterial proteins
necessary in pathogenesis (Maeda, 1996). Puriﬁed
Cwp84 exhibits proteolytic activity against ﬁbronectin,
laminin and type IV collagen, suggestive of a possible
role in infection (Janoir et al., 2004, 2007). However, the
relevance of these host targets is unclear and the activ-
ity observed may be opportunistic in nature rather than
reﬂecting underlying biological function. Pull-down exper-
iments using an inhibitor of SlpA cleavage identiﬁed
Fig. 2. The S-layer locus.
A. Clostridium difﬁcile strain 630 encodes 29 cell wall proteins that use the CWB2 (PF04122) motif for non-covalent anchoring to the cell wall.
Twelve of these, including the S-layer precursor SlpA, are encoded within a single genomic locus (green arrows) that also encodes the S-layer
secretion ATPase SecA2 (red arrow) and ﬁve unrelated proteins (black arrows). The core variable S-layer cassette region is highlighted. An
extensive glycan synthesis cluster is located immediately downstream of cwp7. It is believed that the proteins encoded in this cluster are
responsible for the synthesis of PS-II (Willing et al., 2015).
B. One of the 12 identiﬁed S-layer cassettes (cassette type 11) has a 23.8 kb insertion that includes 19 putative ORFs (Dingle et al., 2013).
Functional predictions of each of the encoded proteins identiﬁed all of the activities necessary for the synthesis of a complex glycan and trans-
fer to a substrate. In cassette type 11, the cwp2 gene is missing and the order of cwp66 and cd2790 is reversed.
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Fig. 3. Organization of the Clostridium difﬁcile cell envelope.
A. C. difﬁcile has a normal Gram positive cell envelope with a surface exposed proteinaceous S-layer on the outer surface. The S-layer is deco-
rated and functionalized by members of the CWP family; shown are the putative adhesin CwpV and cysteine protease Cwp84. Secretion of the
S-layer precursor SlpA and CwpV are dependent on the accessory ATPase SecA2. Following secretion, SlpA is cleaved by Cwp84 (green
arrow), generating the LMW and HMW SLPs. These SLPs form a high-afﬁnity heterodimer that represents the basic subunit of the S-layer.
CwpV also undergoes post-secretion processing via an enzyme-independent auto-proteolytic mechanism. In addition to the S-layer and associ-
ated CWPs, C. difﬁcile possesses numerous other cell surface proteins. The mechanism of secretion and cell wall anchoring of GroEL and
Fbp68 (FbpA) is unclear but both can be detected on the cell surface. The lipoprotein CD0873 and sortase-anchored proteins CbpA and
CD2831 are likely secreted via the canonical Sec pathway. Following secretion, CD0873 is attached to the cell membrane via its lipid anchor
and the sortase substrates are covalently linked to the peptidoglycan (Thr-mDap) by the sortase enzyme CD2718.
B. Domain organization of the proteins shown in A. N-terminal secretion signals are shown as black boxes, the CD0873 lipobox is shown in
grey and the (lipoprotein) signal peptidase cleavage sites are indicated with white arrows. Post-secretion cleavage sites are indicated with black
arrows. Functional domains demonstrated experimentally or identiﬁed using the Pfam database (Finn et al., 2016) are also highlighted. The
sequence and location of sorting motifs are shown above CbpA and CD2831.
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Cwp84 as the SlpA processing protease (Dang et al.,
2010) and when a cwp84 insertional knockout strain was
constructed, SlpA processing was completely abolished
(Kirby et al., 2009). The cwp84 gene is also located
close to slpA in the S-layer cassette (Fig. 2A). Taken
together, this suggests that SlpA is the principal target of
Cwp84. Although potent inhibitors of Cwp84 have been
developed (Dang et al., 2010; Tam Dang et al., 2012), a
cwp84 mutant was fully virulent in the hamster model of
acute infection, suggesting that this protease is not a
viable antimicrobial target (Kirby et al., 2009). As Cwp84
is highly conserved between C. difﬁcile strains, it has
also been investigated as a possible vaccine candidate
(Pechine et al., 2011; Sandolo et al., 2011). Immuniza-
tion with Cwp84 induced a speciﬁc antibody response
and increased survival in the lethal hamster model. How-
ever, complete protection was not achieved and further
investigation will be required to determine if Cwp84 has
potential as a component of an anti-C. difﬁcile vaccine.
A second cysteine protease, Cwp13 is a paralogue of
Cwp84, displaying 63% amino acid identity (de la Riva
et al., 2011). In the absence of Cwp84, Cwp13 can par-
tially substitute in SlpA processing, however, it also dis-
plays proteolytic activity against a sequence in the HMW
region of SlpA, distinct from that recognized by Cwp84
(de la Riva et al., 2011). It has been suggested that
Cwp13 plays a role in the turnover of misfolded proteins
on the cell surface (de la Riva et al., 2011).
CwpV is the largest member of the CWP family and is
encoded outside the S-layer cassette. In addition to N-
terminal CWB2 motifs, CwpV possesses a region of
unknown function ending in a ﬂexible serine-glycine-rich
linker and a C-terminal region containing 4–9 repeats of
79–120 amino acids (Reynolds et al., 2011). Expression
of CwpV is phase-variable, with only 5% of cells in a
population expressing the protein in vitro (Emerson
et al., 2009). However, when expressed, CwpV accounts
for almost 15% of S-layer associated protein. Expression
of CwpV is controlled by a 195 bp invertible switch
located immediately upstream of the gene. The switch is
ﬂanked by imperfect 21 bp inverted repeats that can be
recombined by the site-speciﬁc recombinase RecV,
inverting the intervening DNA (Emerson et al., 2009;
Reynolds et al., 2011). In the ‘OFF’ orientation, a stem
loop terminator is formed that prevents transcriptional
readthrough. In the ‘ON’ orientation, no stem loop is
formed and the gene is expressed. CwpV secretion is
mediated by SecA2 (Fagan and Fairweather, 2011), fol-
lowing which, it is cleaved into a ~42 kDa N-terminal
fragment and a 90–120 kDa C-terminal fragment that
form a non-covalent heterodimeric complex on the cell
surface. CwpV cleavage is via intra-molecular, enzyme-
and cofactor-independent autoproteolysis (Dembek
et al., 2012). The C-terminal-repeat region varies
between strains and ﬁve distinct sequence types have
been identiﬁed to date, types I–V (Reynolds et al.,
2011). As with SlpA, antigenic variability of CwpV may
be a result of host immune or bacteriophage selective
pressure. Indeed, it has been observed that CwpV
expression confers protection against bacteriophage
infection using a novel mechanism that does not affect
phage adsorption but rather prevents phage DNA repli-
cation (Sekulovic et al., 2015), similar to superinfection
exclusion systems. CwpV expression also promotes
auto-aggregation of cells in solid and liquid media (Rey-
nolds et al., 2011) similar to those reported in mouse
models of colonization (Lawley et al., 2009). It is tempt-
ing to suggest that CwpV may play a role in host colo-
nization, but further studies will be required to test this.
Sortase-anchored proteins
In many Gram positive bacteria, surface proteins are
covalently attached to the cell wall by the action of sor-
tases. Staphylococcus aureus makes extensive use of
this anchoring mechanism and the housekeeping sor-
tase, SrtA, has been well characterized (Schneewind
et al., 1992). SrtA recognizes a C-terminal tripartite sig-
nal sequence containing a highly conserved pentapep-
tide cell wall sorting motif, LPxTG. Proteins are then
anchored to the cell wall via the catalytic action of a con-
served cysteine residue of the sortase which cleaves the
LPxTG motif between the threonine and glycine residues
and, subsequently, covalently attaches the substrate pro-
tein to PG precursors (Fig. 3A) (Perry et al., 2002). Six
sortase families, with different functions within the cell,
have been described, all of which recognize different
substrate motifs (Spirig et al., 2011). Only one functional
sortase gene has been identiﬁed in C. difﬁcile, a second
contains an internal stop codon and is considered a
pseudogene (Sebaihia et al., 2006). cd2718 encodes a
sortase that displays 32% identity to S. aureus SrtB
(Donahue et al., 2014) and displays structural character-
istics of class B sortases (Chambers et al., 2015).
CD2718 acts on a sorting motif closely related to that of
S. aureus SrtA, differing at only at the ﬁrst position, (S/
P)PxTG (Donahue et al., 2014; van Leeuwen et al.,
2014). Sortases, although not usually essential for
growth, are often required for virulence and are therefore
considered targets for new anti-infective compounds
(Cascioferro et al., 2014). Small molecule protease inhi-
bitors are able to inhibit the action of C. difﬁcile sortase
which may aid in the development of new CDI-speciﬁc
therapeutics (Donahue et al., 2014). However, the use of
C. difﬁcile sortase as a therapeutic target may prove
ineffective as inactivation of cd2718 does not signiﬁ-
cantly reduce virulence in the hamster model of infection
(Chambers et al., 2015).
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Studies on C. difﬁcile sortase substrates are some-
what limited. Although eight putative sortase substrates
have been identiﬁed in strain 630 (Donahue et al.,
2014), attachment to the cell wall has only been demon-
strated for a few of these (Chambers et al., 2015; Peltier
et al., 2015). Regulation of surface exposed adhesins is
key to the switch between motile and sessile forms
(Boyd and O’Toole, 2012). The collagen-binding protein
CD2831 and putative adhesin CD3246 both depend on
sortase activity for attachment to the cell wall and are
released through the activity of the highly speciﬁc and
unique protease PPEP-1 (Zmp1/CD2830) (Hensbergen
et al., 2015). The bacterial second messenger cyclic-di-
GMP (c-di-GMP) has been associated with the sessile to
motile switch (Romling et al., 2013). c-di-GMP negatively
regulates PPEP-1 expression via a type I c-di-GMP
riboswitch, and induces cd2831 via a type II riboswitch
(Soutourina et al., 2013). Thus, low level of c-di-GMP
reduces expression of CD2831, while also facilitating
release of existing protein from the cell surface and per-
haps facilitating the transition from sessile to motile
forms (Peltier et al., 2015). A PPEP-1 mutant shows sig-
niﬁcantly reduced virulence in the hamster model of
infection, highlighting the importance of adhesin regula-
tion in vivo and suggests that PPEP-1 is a promising
antimicrobial target (Hensbergen et al., 2015).
Collagen-binding protein A (CbpA) has been identiﬁed
as a putative sortase substrate due to the presence of
an apparent SrtB sorting motif (NVQTG) (Tulli et al.,
2013). Although sortase-mediated anchoring has not
been experimentally conﬁrmed, CbpA is surface
exposed. CbpA belongs to the MSCRAMM family (Patti
et al., 1994), which includes proteins that interact with
the host extracellular matrix, and displays high afﬁnity for
collagens I and V, the most common components of ﬁb-
rils. Heterologous expression in Lactococcus lactis
resulted in surface localization and an increased ability
to adhere to both immobilized collagen V and human
ﬁbroblasts (Tulli et al., 2013). Despite these observa-
tions, a cbpA mutant displays no signiﬁcant decrease in
adherence to either immobilized collagen or human
ﬁbroblasts (Tulli et al., 2013). A cbpA mutant also
showed no signiﬁcant difference, compared with the par-
ental strain, in colonization ﬁtness in a competitive
mouse model (Janoir et al., 2013), perhaps due to
redundancy with CD2831 (Hensbergen et al., 2015) and
other adhesion factors. CbpA is therefore unlikely to be
an effective antimicrobial target.
Other cell surface proteins
In addition to the CWP family and sortase substrates,
a number of other proteins are localized to the cell sur-
face, through interaction with the cytoplasmic
membrane or through uncharacterized mechanisms of
cell surface association. Several of these proteins have
been identiﬁed as important colonization factors during
C. difﬁcile infection, facilitating adherence to human
tissue.
Fibronectin-binding protein (Fbp68/FbpA) is another
member of the MSCRAMM family and is surface associ-
ated in C. difﬁcile, despite lacking obvious mechanisms
of cell surface association or a secretion signal (Hen-
nequin et al., 2003). Fbp68 is a manganese-dependent
ﬁbronectin-binding protein, capable of binding to immobi-
lized ﬁbronectin and cultured vero cells (Hennequin
et al., 2003; Lin et al., 2011). An fbp68 mutant displayed
no signiﬁcant defect in adherence to either Caco-2 or
HT29-MTX cells but did show a signiﬁcant decrease in
caecal colonization in a monoxenic mouse model and
was outcompeted by the parental strain in a dixenic
mouse model (Barketi-Klai et al., 2011). Anti-Fbp68 anti-
bodies have been found in CDI patient sera suggesting
that Fbp68 may perhaps be a useful component of a
C. difﬁcile vaccine (Pechine et al., 2005).
Heat shock proteins have been shown to be important
for survival in the host for many pathogenic bacteria
(Z€ugel and Kaufmann, 1999), and C. difﬁcile adherence
to tissue cultures can be increased through varying
stresses including heat shock, acidic pH and low iron
levels (Eveillard et al., 1993; Waligora et al., 1999).
GroEL is a member of the Hsp60 chaperonin family and
its expression is upregulated in response to all of these
stresses (Hennequin et al., 2001a). Co-incubation of
C. difﬁcile with anti-GroEL antibodies or puriﬁed GroEL
signiﬁcantly decreased adherence of C. difﬁcile cells to
cultured vero cells, suggesting that GroEL acts as an
adhesin (Hennequin et al., 2001b). GroEL is also associ-
ated with the cell surface, although it lacks a signal
sequence or obvious mechanism of cell surface associa-
tion (Hennequin et al., 2001a,b). GroEL is an immuno-
genic protein in cell wall extracts of C. difﬁcile and
immunization of mice with recombinant protein reduces
intestinal colonization by C. difﬁcile (Pechine et al.,
2013).
CD0873 is a lipoprotein with 21% sequence identity to
the PsaA protein of Streptococcus pneumoniae, a multi-
functional lipoprotein component of an ABC-type trans-
porter involved in adhesion to the host cell (Rajam et al.,
2008; Kovacs-Simon et al., 2014). Immunoﬂuorescence
microscopy revealed that CD0873 is surface exposed, and
likely anchored to the membrane through attached acyl
moieties. Although no in vivo experiments have been
reported, a mutant strain incapable of producing CD0873
is unable to bind Caco-2 cells, suggesting a role in adhe-
sion to enteric cells. CD0873 is widely conserved (Kovacs-
Simon et al., 2014) and therefore represents an interesting
antimicrobial target and vaccine candidate.
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The cell surface as a target of phage therapy
Bacteriophage and phage-like particles have great
potential as anti-C. difﬁcile therapeutics (Hargreaves and
Clokie, 2014). Although no C. difﬁcile phage receptors
have been identiﬁed to date, the S-layer, CWPs and cell
wall polysaccharides are all likely candidates. Indeed, it
is possible that the evolution of S-layer sequence diver-
sity is driven by phage predation, at least in part. The
long evolutionary history of C. difﬁcile–phage interactions
is apparent in the genome, with numerous prophage
(Sebaihia et al., 2006), an extensive CRISPR system
(Hargreaves et al., 2014) and an unusual resistance sys-
tem based on the phase-variable protein CwpV (Sekulo-
vic et al., 2015). Although no strictly lytic phage have
been identiﬁed to date, a number of studies have
demonstrated the utility of phage therapy against C. difﬁ-
cile (Ramesh et al., 1999; Meader et al., 2010, 2013;
Nale et al., 2015). ΦCD140 has been successfully used
to treat CDI in hamsters, with 14 of 18 hamsters surviv-
ing a lethal challenge model (Ramesh et al., 1999).
However, although the phage therapy was successful, it
failed to prevent re-infection when surviving hamsters
were re-challenged 2 weeks later. Two recent studies
have also demonstrated the potential of phage therapy
in vitro. ΦCD27 dramatically reduced the number of
viable C. difﬁcile and reduced production of the toxins,
TcdA and TcdB, in both batch fermentation (Meader
et al., 2010) and an in vitro gut model (Meader et al.,
2013), with no apparent effect on the microbiota. How-
ever, these studies also highlight the therapeutic limita-
tions of lysogenic phage. In one replicate, ΦCD27 failed
to prevent C. difﬁcile proliferation in the in vitro gut
model and this was attributed to early lysogeny (Meader
et al., 2013). It has also been reported that lysogeny
with another phage, ΦCD38-2, can lead to an increase
in toxin production by an epidemic ribotype 027 strain
(Sekulovic et al., 2011). One possible solution to this
potential problem is the use of a varied phage cocktail
rather than a single phage species. In one recent study,
a panel of seven distinct phage species caused signiﬁ-
cant lysis of C. difﬁcile and prevented appearance of
resistant, lysogenic clones (Nale et al., 2015). This same
phage cocktail delayed onset of symptoms by 33 h in
the hamster model of acute disease.
Phage tail-like particles are also an interesting alterna-
tive to traditional phage therapy. Some C. difﬁcile strains
produce R-type bacteriocins that display antibacterial
activity against other strains of C. difﬁcile (Gebhart et al.,
2012). These bacteriocins have similar structure to the
tail ﬁlaments of Myoviridae phages of C. difﬁcile, includ-
ing ΦCD119 and ΦCD2, and presumably kill C. difﬁcile
by puncturing the cell envelope and dissipating the
membrane potential. These naturally occurring
bacteriocins have been modiﬁed to increase stability and
have demonstrated impressive activity in vivo in a
mouse model of infection. Importantly, killing is highly
speciﬁc and these bacteriocins do not perturb the gut
microbiota (Gebhart et al., 2015).
Conclusion
Clostridium difﬁcile is a major cause of morbidity and
mortality worldwide and is the leading cause of antibi-
otic-associated diarrhoea. Dysbiosis, normally as a result
of antibiotic treatment, is a prerequisite for CDI. Although
it is encouraging to note the resurgence in research
aimed at the discovery and development of new broad-
spectrum antibiotics, it is clear that we must take a more
targeted approach to the treatment and prevention of
CDI. The structure and function of the cell envelope is
critical to our understanding of bacterial pathogenesis
and also in the search for novel therapeutic and vaccine
candidates. The recent surge in interest in C. difﬁcile
pathogenesis and the development of a genetic toolbox
for the precise manipulation of the Clostridia has greatly
improved our understanding of cell envelope architecture
and function. Several components of the envelope show
promise as potential drug or vaccine targets, including
an unusual PG, at least two conserved secondary wall
polymers and a large number of conserved surface pro-
teins. Further study of the cell envelope in years to come
will hopefully lead to development of new C. difﬁcile-spe-
ciﬁc treatments.
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